Document is current

Article History

Received: 8 June 2025

Accepted: 16 July 2025

First Online: 25 July 2025

Declarations

:

: KK received lecture Fees from Boehringer Ingelheim Japan, Eli Lilly Japan, Novo Nordisk Pharma, Mitsubishi Tanabe, Daiichi Sankyo, Sumitomo Pharma, Kowa, Kyowa Kirin, Taisho, AstraZeneca, Bayer, Novartis, Otsuka. KK is currently collaborated with Boehringer Ingelheim Japan, Boehringer-Ingelheim (Germany), Kowa, Bayer, Mitsubishi Tanabe. KK received research support from Boehringer Ingelheim Japan, Kowa, Nipro, Life Scan. YY and MO has no conflicts of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Committee of the Faculty of Medicine, Shimane University (Approval No. 20230328–1, approved at 2023.5.8).

: We published an opt-out document so that the participants could withdraw from the study at any time for 6 months periods. (Approval No. 20230328–1, approved at 2023.5.8).